Latest News

(UroToday.com) PSMA-targeted radionuclide therapy (TRT) is one of the most promising investigational therapies in prostate cancer currently. In the phase II TheraP trial and the phase III VISION trial, 177-lutetium-PSMA-617 has demonstrated better outcomes compared to the current standard of care treatment options for patients who have received many lines of therapy for metastatic castration resistant […]

(UroToday.com) Prostate-specific membrane antigen (PSMA)-targeted imaging has rapidly gained interest and utilization in patients with prostate cancer. Recently, two approaches (68-Gallium and Piflufolastat F-18 [PYLARIFY, previously known as 18F-DCFPyL]) have gained FDA approval for prostate cancer patients with suspected recurrence based on elevated PSA. This is driven by a proven ability to better localize and determine […]

(UroToday.com) The Society of Urologic Oncology (SUO) 2021 annual meeting in Orlando, FL hosted a thought-provoking presentation by Dr. Pavlos Msaouel, MD, Ph.D. regarding the future of adjuvant therapy for high-risk non-metastatic renal cell carcinoma (RCC). Dr. Msaouel began his talk by presenting the seminal data from KEYNOTE-564 evaluating adjuvant pembrolizumab (KEYTRUDA ®) after nephrectomy […]

(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included a kidney cancer session and a presentation by Dr. Ari Hakimi discussing clinical and genomic updates in sarcomatoid renal cell carcinoma (RCC). Dr. Hakimi started by noting that sarcomatoid dedifferentiation is seen in ~5% of all kidney cancer, and ~20% of patients with metastatic disease. […]

(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included a penile cancer session and a presentation by Dr. Juanita Crook discussing updates of the global InPACT trial. Penile cancer is rare and evidence to establish practice standards is limited. There is suggestion of benefit with neoadjuvant chemotherapy, as well as chemo-radiation being effective for […]

(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included a penile cancer session and a presentation by Dr. Srikala Sridhar discussing novel systemic therapeutic approaches in penile cancer. Dr. Sridhar started by highlighting that penile cancer is a rare malignancy, comprising <0.5% of all male cancers, with a significant geographic variation.

(UroToday.com) The Society of Urologic Oncology (SUO) 2021 annual meeting in Orlando, FL hosted the 2021 European Association of Urology (EAU) Annual Lecture. Dr. Michael Cookson graciously presented Dr. Maria Carmen Mir, MD, PhD, FEBU as the invited guest speaker and emphasized the importance of the SUO EAU Exchange Lectureship Program that serves to strengthen the […]

Phase III ARASENS trial meets primary endpoint of overall survival for NUBEQA in combination with docetaxel and androgen deprivation therapy (ADT) versus docetaxel and ADT, a standard of care in men with metastatic hormone-sensitive prostate cancer (mHSPC) Bayer plans to present these pivotal data at a forthcoming scientific congress and discuss them with health authorities […]

The widespread use of ultrasonography for the investigation of common urological conditions, such as infertility or pain, has resulted in an increased incidence of incidental non-palpable testicular masses.

Comorbidity along with tumor and patient characteristics is taken into account when deciding for the surgical treatment of renal cell carcinoma (RCC). Comorbidity has also been used as an independent predictive factor for postoperative complications of several major urological procedures including radical nephrectomy for RCC.